---
title: Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer
nct_id: NCT02869282
overall_status: WITHDRAWN
sponsor: Institut Bergonié
study_type: OBSERVATIONAL
primary_condition: Prostate Cancer
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02869282.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02869282"
ct_last_update_post_date: 2025-09-17
last_seen_at: "2026-05-12T06:11:04.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer

**Official Title:** Study Of The Expression Of Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer

**NCT ID:** [NCT02869282](https://clinicaltrials.gov/study/NCT02869282)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** Principal investigator left the study center and nobody took over the study.
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** Institut Bergonié
- **Conditions:** Prostate Cancer
- **Start Date:** 2011-06
- **Completion Date:** 2016-12
- **CT.gov Last Update:** 2025-09-17

## Brief Summary

Multicentric, observational, prospective, non-interventional study with occasional biological sample collection (serum bank, urine bank and tumor bank)

## Detailed Description

This project is an exploratory study, based on the hypothesis of involvement of chemokines in hormonal escape of prostate cancers.

The two main objectives are:

* To describe the variations in expression of chemokines in serum and urine level in patients with prostate cancer
* And to study the disease stage and intra-prostatic concentrations of chemokines based on serum and urine concentrations of chemokines before treatment initiation.

These estimates can be used in future trials set up for the management of prostate cancer

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients with a localized or metastatic prostate adenocarcinoma for which a new treatment will be implemented (hormone therapy for single biological relapse or relapses and metastatic hormone-sensitive) or chemotherapy (for biological relapses and / or metastatic hormone-resistant)
* Patients with a detectable PSA (Prostate-Specific Antigen)
* Patients who signed an informed consent
* Patients over 18 years
* Patients belonging to the social security scheme

Exclusion Criteria:

* Active Hepatitis B or C virus
* HIV positive
* Patients who have received prior chemotherapy
* Patients with a second neoplasia treated in the last 5 years
```

## Arms

- **Prospective cohort** — Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.

## Interventions

- **Blood samples** (OTHER) — Additional blood samples at baseline, 6, 12, 18 and 24 months.
- **Urine samples** (OTHER) — Additional urine samples at baseline, 6, 12, 18 and 24 months.

## Primary Outcomes

- **Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical** _(time frame: At baseline)_
- **Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical** _(time frame: At 6 months)_

## Locations (1)

- Institut Bergonié, Bordeaux, France

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.institut bergonié|bordeaux||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02869282.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02869282*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*